OCA
ITCI

Octagon Capital Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Octagon Capital Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-94,700
Closed -$5.13M – 46
2023
Q1 		$5.13M Sell
94,700
-126,253
-57% -$6.1M 0.74% 24
2022
Q4 		$11.7M Hold
220,953
– – 1.82% 13
2022
Q3 		$10.3M Buy
+220,953
New +$11.5M 1.77% 13

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Octagon Capital Advisors's ITCI Position: Q2 2023 in Review

Octagon Capital Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 94,700 shares — an estimated $5.13M sold.

Octagon Capital Advisors first reported a position in ITCI in Q3 2022 and held it in 3 quarters. The position peaked at $11.7M in Q4 2022. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Octagon Capital Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 94,700 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $5.13M.
  • Octagon Capital Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 3 quarters.
  • Octagon Capital Advisors's Intra-Cellular Therapies Inc. position peaked at $11.7M in Q4 2022.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Octagon Capital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.